Large. Infections caused by microflora sensitive to the drug: respiratory tract, including pneumonia, bronchitis; skin and subcutaneous tissue; intraabdominal infections, including peritonitis and biliary tract infections; gynecological; septicaemia. Empirical therapy of patients with neutropenic fever. Prevention of postoperative complications in intraabdominal surgery. Children. Pneumonia; urinary tract infections, including pyelonephritis; skin and subcutaneous tissue infections; septicaemia; empirical therapy of patients with neutropenic fever; bacterial meningitis.
active substance: sefepime;
1 vial contains * cefepime hydrochloride equivalent to cefepime 500 mg or 1000 mg.
* sterile mixture of cefepime hydrochloride and L-arginine.
Extencef Dosage form
Powder for solution for injection.
Basic physical and chemical properties: powder from white to light yellow color.
Antimicrobials for systemic use. Other b-lactam antibiotics. Cephalosporins of the fourth generation. Cefepime. ATX code J01D E01.
Cefepime inhibits the synthesis of enzymes in the bacterial cell wall and has a broad spectrum of action against various gram-positive and gram-negative bacteria. Cefepime is highly resistant to hydrolysis by most b-lactamases, has little affinity for b-lactamases encoded by chromosomal genes, and rapidly penetrates gram-negative bacterial cells.
Cefepime is active against the following microorganisms:
gram-positive aerobes: Staphylococcus aureus and Staphylococcus epidermidis (including their b-lactamase-producing strains); other strains of staphylococci, including S. hominis, S. saprophyticus; Streptococcus pyogenes (group A streptococci); Streptococcus agalactiae (group B streptococci); Streptococcus pneumoniae (including strains with medium resistance to penicillin – minimum inhibitory concentration from 0.1 to 1 μg / ml); other b-hemolytic streptococci (groups C, G, F), S. bovis (group D), streptococci of Viridans group. (Most strains of enterococci, such as Enterecoccus faecalis, and methicillin-resistant staphylococci are resistant to most cephalosporin antibiotics, including cefepime);
Infections caused by drug-sensitive microflora:
respiratory tract, including pneumonia, bronchitis;
skin and subcutaneous tissue;
intra-abdominal infections, including peritonitis and biliary tract infections;
Empirical therapy of patients with neutropenic fever.
Prevention of postoperative complications in intra-abdominal surgery.
urinary tract infections, including pyelonephritis;
skin and subcutaneous tissue infections;
empirical therapy of patients with neutropenic fever;
Hypersensitivity to cefepime or L-arginine, as well as to cephalosporin class antibiotics, penicillins or other b-lactam antibiotics.
Interaction with other medicinal products and other forms of interaction
When high doses of aminoglycosides are co-administered with Extencef, renal function should be closely monitored due to the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. Nephrotoxicity was observed after concomitant use of other cephalosporins with diuretics such as furosemide.
Extencef at a concentration of 1 to 40 mg / ml is compatible with the following parenteral solutions: 0.9% sodium chloride solution for injection; 5 and 10% glucose solutions for injection; 6M sodium lactate solution for injection, 5% glucose solution and 0.9% sodium chloride solution for injection; Ringer’s solution with lactate and 5% glucose solution for injection.
To avoid possible drug interactions with other drugs, Extencef solutions (like most other b-lactam antibiotics) are not administered concomitantly with solutions of metronidazole, vancomycin, gentamicin, tobramycin sulfate, and netilmicin sulfate. In case of prescribing the drug Extencef with these drugs, enter each antibiotic separately.